THE STANLEY MEDICAL RESEARCH INSTI… - Form 990 Financial Data

🔒

Financial Vulnerability Assessment (Tuckman-Chang)

4 risk indicators measuring financial stability and operational resilience

Sign in with your work email to view Tuckman-Chang indicators

Financial Trends

Organization Details

Formation Year

2001

Legal Domicile

Principal Officer

MAREE J WEBSTER

Phone

3015710760

Tax Period

2023-01-01 to 2023-12-31

THE STANLEY MEDICAL RESEARCH INSTITUTE, founded in 2001, is a community nonprofit in the Medical Research sector that reported $4.6M in total revenue in fiscal year 2023. Revenue grew 10% year-over-year, indicating healthy expansion. Expenses of $6.6M exceeded revenue, resulting in a 43% operating deficit.

Mission

TO FIND THE CAUSE(S) OF AND BETTER PHARMACOLOGICAL TREATMENTS FOR SCHIZOPHRENIA AND BIPOLAR DISORDER.

Program Service Accomplishments

Program 1

Expenses: $3,066,950

INFECTIOUS AND NEUROVIROLOGY: SMRI IS THE MAJOR RESEARCH INSTITUTION IN THE WORLD FOCUSING ON INFECTIOUS AGENTS AS A POSSIBLE CAUSE OF SCHIZOPHRENIA AND BIPOLAR DISORDER. THE CENTER FOR THIS RESEARCH IS THE STANLEY LABORATORY OF DEVELOPMENTAL NEUROVIROLOGY AT JOHNS HOPKINS UNIVERSITY IN BALTIMORE. THIS LABORATORY WORKS CLOSELY WITH SMRI-FUNDED RESEARCHERS AT SEVERAL OTHER INSTITUTIONS. THE MAIN TARGETS OF THIS RESEARCH ARE TOXOPLASMA GONDII, THE HERPES FAMILY OF VIRUSES, AND ENDOGENOUS RETROVIRUSES.

Program 2

Expenses: $1,532,282

TREATMENT TRIALS: DURING 2023, SMRI SUPPORTED 21 TRIALS FOR THE TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DISORDER. MOST OF THESE WERE DRUGS THAT ARE AVAILABLE TO TREAT OTHER CONDITIONS AND FOR WHICH...

TREATMENT TRIALS: DURING 2023, SMRI SUPPORTED 21 TRIALS FOR THE TREATMENT OF SCHIZOPHRENIA OR BIPOLAR DISORDER. MOST OF THESE WERE DRUGS THAT ARE AVAILABLE TO TREAT OTHER CONDITIONS AND FOR WHICH THERE WAS REASON TO BELIEVE THEY MIGHT ALSO BE EFFECTIVE FOR PSYCHIATRIC DISORDERS. IN ALMOST ALL CASES, PHARMACEUTICAL COMPANIES ARE UNLIKELY TO SUPPORT SUCH TRIALS BECAUSE THE DRUG IS ALREADY GENERIC OR CANNOT BE PATENTED. SMRI IS SUPPORTING MORE SUCH TREATMENT TRIALS THAN ANY OTHER ORGANIZATION IN THE WORLD.

Program 3

Expenses: $1,521,275

NEUROPATHOLOGY: BRAIN TISSUE REPOSITORY AND NEUROPATHOLOGY LABORATORY: STORES AND PROCESSES POSTMORTEM BRAIN TISSUE, LIVER, SPLEEN, SERUM AND CSF FROM PEOPLE WITH SCHIZOPHRENIA, BIPOLAR DISORDER...

NEUROPATHOLOGY: BRAIN TISSUE REPOSITORY AND NEUROPATHOLOGY LABORATORY: STORES AND PROCESSES POSTMORTEM BRAIN TISSUE, LIVER, SPLEEN, SERUM AND CSF FROM PEOPLE WITH SCHIZOPHRENIA, BIPOLAR DISORDER, MAJOR DEPRESSION AND FROM NORMAL CONTROL SUBJECTS. SAMPLES ARE MADE AVAILABLE TO SCIENTISTS AROUND THE WORLD. ALL RESEARCH DATA COLLECTED ON THE SPECIMENS IS RETURNED TO THE SMRI PUBLICALLY AVAILABLE WEB-BASED INTERACTIVE NEUROPATHOLOGY DATABASE FOR FURTHER ANALYSIS.

🔒

Trantor Score

Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency

Sign in to view Trantor Score and financial metrics

Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)

Financial Overview (2023)

Revenue Breakdown

Contributions & Grants $13,900

Program Service Revenue $0

Investment Income $4,607,141

Other Revenue $7,570

TOTAL REVENUE $4,628,611

Expense Breakdown

Grants Paid $4,604,525

Salaries & Benefits $1,067,072

Fundraising Expenses $0

Program Expenses $6,223,002

Other Expenses $933,554

TOTAL EXPENSES $6,605,151

Year-over-Year Comparison

	2023	2022	Change
Revenue	$4,628,611	$4,203,285	+0.1%
Expenses	$6,605,151	$6,508,094	+0.0%
Net Income	$-1,976,540	$-2,304,809	-0.1%

Key Indicators

✓ Grants to Organizations ✗ Grants to Individuals ✗ Lobbying ✗ Political Activity ✓ Foreign Activities ✗ Donor Advised Fund ✓ Schedule B Required

🔒

Financial Health Indicators

Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics

Financial Distress Indicator

Liquidity & Cash Position

Sign in to view all financial metrics

Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics

Governance

Voting Members

Independent Members

Employees

Volunteers

Governance Policies

✗ Conflict of Interest Policy

✗ Whistleblower Policy

✓ Document Retention Policy

Special Practices & Reported Activities

✗ Operated a School

✗ Operated a Hospital

✗ Provided First Class Travel

⚠ Reported Conflict of Interest

✗ Reported Asset Diversion

✗ Excess Benefit Transaction

✗ Made Political Expenditures

✗ Engaged in Lobbying

✗ Operated Donor Advised Fund

✗ Maintained Art Collections

✗ Filed Form 720

Compensation of Officers, Directors & Key Employees

Total Officers

$264,460

Total Directors

$328,169

Key Employees

Highest Compensated

reported

Name	Title	Hours/Week	Role	Reportable Comp	Other Comp	Total
MAREE J WEBSTER SEE SCHED L	EXECUTIVE DIRECTOR	40.00	Officer Director	$224,382	$40,078	$264,460
ROBERT YOLKEN SEE SCHED O	TRUSTEE	5.00	Director	$36,000	$0	$36,000
E FULLER TORREY SEE SCHED O	ASSOCIATE DIRECTOR FOR REA	24.00	Director	$24,660	$3,049	$27,709
STEVEN JONES	TRUSTEE	0.10	Director	$0	$0	$0
BARBARA TORREY	TRUSTEE	0.10	Director	$0	$0	$0
JONATHAN STANLEY	TRUSTEE	0.10	Director	$0	$0	$0
MICHAEL KNABLE SEE SCHED L	TRUSTEE	0.10	Director	$0	$0	$0
SANGHYEON KIM	ASSOC. DIR. OF DATABASE MG	40.00	Highest	$110,127	$49,679	$159,806

Note: Compensation data is self-reported by the organization on their Form 990. "Reportable Comp" includes salary, bonuses, and other reportable compensation from the organization and related organizations. "Other Comp" includes benefits, deferred compensation, and non-taxable benefits.

Historical Data

Year	Revenue	Expenses	Assets	Net Income
2024	No data	No data	No data	No data
2023	$4,628,611	$6,605,151	$85,710,224	$-1,976,540
2022	$4,203,285	$6,508,094	$78,471,572	$-2,304,809
2021	$6,081,519	$7,003,852	$99,254,523	$-922,333
2020	$3,578,535	$6,347,201	$90,271,236	$-2,768,666
2019	$2,786,019	$9,387,885	$84,721,035	$-6,601,866
2018	$8,482,259	$11,058,222	$78,671,552	$-2,575,963

THE STANLEY MEDICAL RESEARCH INSTITUTE